DBV Technologies is making progress in filing the BLA application for VIASKIN® Peanut

DBV Technologies announced progress in preparing its Biologics License Application (BLA) for the VIASKIN® Peanut patch for children aged 4 to 7. Working with the FDA, the biopharmaceutical company is optimizing the review process to ensure efficient submission in the third quarter of 2026. Discussions with the FDA have yielded actionable feedback on the structure and presentation of the data, without requiring additional data.

These consultations aim to ensure a swift and thorough review of the BLA. According to Daniel Tassé, Managing Director of DBV, these discussions are essential to strengthening the license application, as the VIASKIN patch is a product without regulatory precedent. A conference call for investors was held to discuss this progress.